GoodRx vs Willow

Neither GoodRx nor Willow has an FDA warning letter on record. No price lines up like for like: GoodRx and Willow publish prices for different products.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

GoodRx / Willow

GoodRx logo

GoodRx

7.8/10

Willow logo

Willow

7.3/10

FDA warning letters
None on record
None on record
Pharmacy
Brand-name only; no compounding
Lowest standing price
$149/moFoundayo (orforglipron) pill
$299/moCompounded semaglutide injection
States
48 states
35 states
Checked
Prices captured Record checked October 2026
Prices captured Record checked September 2026

Neither GoodRx nor Willow pays us. Links to them earn nothing. Scores: GoodRx 7.8, Willow 7.3. How we are paid

What the record shows

  1. 01

    Neither GoodRx nor Willow has an FDA warning letter on record.

  2. 02

    Willow names five pharmacies. GoodRx sells brand-name medication only.

  3. 03

    No price lines up like for like: GoodRx and Willow publish prices for different products.

  4. 04

    Only GoodRx lists a price for brand-name tirzepatide pen and Foundayo (orforglipron) pill. Only Willow lists a price for compounded semaglutide injection and compounded tirzepatide injection.

  5. 05

    GoodRx covers 13 states Willow does not.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

GoodRx

Willow

Compounded semaglutide injection
Not sold or not priced

$299/mo

$3,588 a year

Compounded tirzepatide injection
Not sold or not priced

$399/mo

$4,788 a year

Brand-name tirzepatide pen

$299/mo

$3,588 a year

Not sold or not priced
Foundayo (orforglipron) pill

$149/mo

$1,788 a year

Not sold or not priced
Price includes
Not stated
Medication, clinician visits, shipping
Cancel any time
Yes, stated
Yes, stated
Minimum term
None
None
Refunds
Services and medication are generally non-refundable
Full refund if you cancel before the prescription is sent to the pharmacy; none once the medication is compounded

Read off each seller’s own pages. GoodRx: October 30, 2026. Willow: July 10, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for GoodRx

7.8/10
  • Sells brand-name tirzepatide pen and Foundayo (orforglipron) pill, which Willow does not price
  • Lists 48 states against 35

The case for Willow

7.3/10
  • Sells compounded semaglutide injection and compounded tirzepatide injection, which GoodRx does not price

Scores

GoodRx 7.8 · Willow 7.3 out of 10. Six weighted parts.

Value25%

8.7A
vs
B
3.0

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

5.0A
vs
B
8.0

Trust & Safety15%

6.0A
vs
B
9.0

Accessibility10%

9.7A
vs
B
7.6

Support10%

5.0A
vs
B
7.0

The score is the same formula for every seller. Payment does not enter it. Method

GoodRx vs Willow: questions

Neither GoodRx nor Willow has an FDA warning letter on record. Letters are matched to a seller by company, domain and address, never by a similar name.
Willow names five pharmacies. GoodRx sells brand-name medication only. A 503A pharmacy compounds for named patients on a prescription; a 503B outsourcing facility is registered with FDA and inspected under federal manufacturing rules.
No price lines up like for like: GoodRx and Willow publish prices for different products. We only set two prices against each other when they are for the same product and both are standing month-to-month or 4-week rates.
GoodRx states you can cancel at any time; refunds: services and medication are generally non-refundable. Willow states you can cancel at any time; refunds: full refund if you cancel before the prescription is sent to the pharmacy; none once the medication is compounded.
Neither GoodRx nor Willow pays us. Links to them earn nothing. Scores: GoodRx 7.8, Willow 7.3.

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks